Cynapsus Therapeutics Reports Results From Healthy Volunteer Study for Advanced Parkinson’s Disease Drug

Cynapsus Therapeutics Inc. (TSXV:CTH,OTCQX:CYNAF) announced that, on a healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine, the interim CTH-104 study results indicate that a higher load of drug on the strip results in a higher amount of drug entering the blood stream. Apomorphine is the only drug approved specifically for the treatment of acute motor fluctuations/hypomobility in patients with advanced Parkinson’s disease.

As quoted in the press release:

Key Findings

• Comparing the increased dose of the 25mg (APL-130277) strip used in CTH-104 to that of the 15mg strip previously used in CTH-103, indicates that a higher concentration of apomorphine was achieved. In this first group of subjects, sublingual delivery of the higher 25mg strip dose resulted in more adverse events with a greater severity than seen with the 15 mg dose. The side effects were mild to moderate and were not defined to be dose limiting.
• In this first group of subjects, the PK profile of the 25mg APL-130277 dose strip indicates that exposure increased as compared to 15mg strip and achieved a concentration associated with an expected minimum efficacious concentration (i.e. approximately 3ng/ml) for over 2 hours.

Click here to read the Cynapsus Therapeutics Inc. (TSXV:CTH,OTCQX:CYNAF) press release